3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
2
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
63
Colonic Neoplasms
29
Rectal Neoplasms
25
Neoplasm Metastasis
11
Stomach Neoplasms
8
Carcinoma, Hepatocellular
7
Pancreatic Neoplasms
6
Neoplasms
6
Esophageal Neoplasms
4
Adenocarcinoma Of Esophagus
4
Liver Neoplasms
3
Ovarian Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Recurrence
1
Prostatic Neoplasms
1
Postoperative Complications
1
Peritoneal Neoplasms
1
Operable T2-3N+M0 Rectal Cancer (Stage III)
1
Neuropathy, Painful
1
Neuralgia
1
Neoplasm Recurrence, Local
1
Melanoma
1
Malignant Solid Tumour
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Gastrointestinal Neoplasms
1
Cold Hypersensitivity
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Basal Cell
1
Interventions
Carboplatin
341
Paclitaxel
262
Cisplatin
233
Pemetrexed
226
Docetaxel
206
Erlotinib Hydrochloride
193
Gemcitabine
178
pembrolizumab
137
Bevacizumab
121
Radiotherapy
118
Nivolumab
84
Gefitinib
73
Vinorelbine
64
Cetuximab
58
atezolizumab
47
Afatinib
46
durvalumab
44
osimertinib
41
Radiosurgery
35
Ipilimumab
34
Drug Therapy
32
Taxes
30
Albumin-Bound Paclitaxel
29
130-nm albumin-bound paclitaxel
29
Surgical Procedures, Operative
28
Etoposide
25
Irinotecan
24
Sorafenib
21
Cyclophosphamide
20
Radiation
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Non-Small-Cell Lung
×
Folfox protocol
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled